Chiome Bioscience Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
68
- Stock Symbol
-
4583
- Investments
-
5
- Share Price
-
$1.54
- (As of Thursday Closing)
Chiome Bioscience General Information
Description
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.
Contact Information
Website
www.chiome.co.jpCorporate Office
- Sumitomo Fudosan Nishi-Shinjuku Building 6
- 3-12-1 Honmachi, Shibuya-ku
- Tokyo, 151-0071
- Japan
Corporate Office
- Sumitomo Fudosan Nishi-Shinjuku Building 6
- 3-12-1 Honmachi, Shibuya-ku
- Tokyo, 151-0071
- Japan
Chiome Bioscience Stock Performance
As of 16-Jan-2025, Chiome Bioscience’s stock price is $1.54. Its current market cap is $94M with 61.2M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.54 | $1.71 | $0.52 - $1.97 | $94M | 61.2M | 12M | -$0.14 |
Chiome Bioscience Financials Summary
As of 30-Jun-2024, Chiome Bioscience has a trailing 12-month revenue of $3.94M.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 42,270 | 42,222 | 52,127 | 51,577 |
| Revenue | 3,939 | 4,857 | 4,800 | 6,492 |
| EBITDA | (7,459) | (8,624) | (9,398) | (13,315) |
| Net Income | (7,513) | (8,683) | (9,457) | (13,476) |
| Total Assets | 9,678 | 12,419 | 16,897 | 20,330 |
| Total Debt | 1,815 | 2,063 | 1,403 | 1,590 |
Chiome Bioscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Chiome Bioscience Patents
Chiome Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023300945-A1 | Fusion protein | Pending | 30-Jun-2022 | ||
| AU-2023213334-A1 | Anti-human cxcl1 antibody | Pending | 27-Jan-2022 | ||
| EP-4471057-A1 | Anti-human cxcl1 antibody | Pending | 27-Jan-2022 | ||
| CA-3233968-A1 | Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent | Pending | 15-Oct-2021 | ||
| AU-2022368026-A1 | Antibody or fragment thereof binding specifically to mertk, and anti-tumor agent | Pending | 15-Oct-2021 | C07K16/40 |
Chiome Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Chiome Bioscience Investments & Acquisitions (5)
Chiome Bioscience’s most recent deal was a Merger/Acquisition with Biotechnol for . The deal was made on 01-Dec-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biotechnol | 01-Dec-2018 | Merger/Acquisition | Biotechnology | ||
| Trans Chromosomics | 10-Feb-2017 | Corporate | Drug Discovery | ||
| EVEC | 30-Mar-2016 | Later Stage VC | Drug Discovery | ||
| LivTech | 13-Mar-2015 | Secondary Transaction - Private | Biotechnology | ||
| LivTech | 25-Dec-2013 | Merger/Acquisition | Biotechnology |
Chiome Bioscience ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Laboratory Equipment and Services
Subindustry
Rank
Percentile
Chiome Bioscience FAQs
-
When was Chiome Bioscience founded?
Chiome Bioscience was founded in 2005.
-
Where is Chiome Bioscience headquartered?
Chiome Bioscience is headquartered in Tokyo, Japan.
-
What is the size of Chiome Bioscience?
Chiome Bioscience has 68 total employees.
-
What industry is Chiome Bioscience in?
Chiome Bioscience’s primary industry is Drug Discovery.
-
Is Chiome Bioscience a private or public company?
Chiome Bioscience is a Public company.
-
What is Chiome Bioscience’s stock symbol?
The ticker symbol for Chiome Bioscience is 4583.
-
What is the current stock price of Chiome Bioscience?
As of 16-Jan-2025 the stock price of Chiome Bioscience is $1.54.
-
What is the current market cap of Chiome Bioscience?
The current market capitalization of Chiome Bioscience is $94M.
-
What is Chiome Bioscience’s current revenue?
The trailing twelve month revenue for Chiome Bioscience is $3.94M.
-
What is Chiome Bioscience’s annual earnings per share (EPS)?
Chiome Bioscience’s EPS for 12 months was -$0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
